Get Well in the RNAi Way-RNAi, A Billion Dollar Baby in TherapyUtpal Bhadra1*, Manika Pal-Bhadra1 and Paromita Das2
- *Corresponding Author:
- Utpal Bhadra
CSIR - Centre for Cellular and Molecular Biology
Uppal Road, Hyderabad-500 007, India
Email: [email protected]
Received date: February 19, 2016; Accepted date: February 25, 2016; Published date: March 03, 2016
Citation: Bhadra U, Pal-Bhadra M, Das P (2016) Get Well in the RNAi Way-RNAi, A Billion Dollar Baby in Therapy. Mol Biol 5:158. doi: 10.4172/2168-9547.1000158
Copyright: © 2016 Bhadra U, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Disease therapy based on genetic materials is now a reality. The technique of gene silencing also called as RNA interference (RNAi) keeps our hopes alive. RNAi based drugs have now advanced steps closer towards clinical trials. The powerful in-vivo RNAi machinery and its delicate factors apprehend that RNAi-dependent therapies might create a billion dollar business against the pathogenic organisms and disease for which treatment options are currently restricted conventionally. Recent years have highlighted both the promises and challenges in delivery of different RNAi therapeutics. Apart from the delivery, the design, stability and degradation of RNAi based effective molecules appears to be the major lime light to challenge the conventional drug safety concerns and ensures to be the most powerful gene recovery in future which execute billion dollar business hope.